AMGEN INC
Total Alternative Signals
Weighted Sentiment
Avg Materiality Score
Signal Distribution
Alternative Data Signal Feed
Unlock Alternative Signals Feed
Access the complete, parsed materiality analysis, long-term investment theses, and direct feed links for AMGEN INC. Programmatic API and Webhooks available.
Signal Event Report - FIGI BBG000BBS2Y0
Amgen was granted a patent for IL-10 muteins and fusion proteins, strengthening its intellectual property in a specific therapeutic area.
This patent enhances Amgen's long-term competitive advantage by protecting its innovative therapeutic compounds, potentially leading to future revenue streams.
Signal Event Report - FIGI BBG000BBS2Y0
Amgen recorded its most recent import shipment on May 27, 2026, confirming active and ongoing international supply chain operations.
This event indicates Amgen's continued engagement in global trade and supply chain activities, which is a normal and necessary aspect of its pharmaceutical business operations, suggesting operational stability.
Signal Event Report - FIGI BBG000BBS2Y0
Amgen received European Commission approval for IMDYLLTRA for small cell lung cancer, a positive development, but simultaneously faces an FDA proposal to withdraw Tavneos from the U.S. market due to data integrity and safety concerns, including patient deaths. Amgen is initiating an independent review for Tavneos.
The approval of IMDYLLTRA offers a new revenue stream and market opportunity in Europe, but the significant regulatory and safety risks associated with Tavneos pose a serious threat to Amgen's autoimmune franchise and overall financial stability. Investors should monitor the outcome of the Tavneos review closely as it could materially impact future earnings and market perception.
Signal Event Report - FIGI BBG000BBS2Y0
Morgan Stanley raised its price target for Amgen, citing a strong start for its drug Uplizna. This indicates positive analyst sentiment regarding the drug's market performance and contribution to Amgen's financials.
The strong performance of Uplizna suggests a positive trajectory for Amgen's product pipeline and revenue growth, reinforcing the investment case for its innovative medicines. This could lead to sustained financial performance and shareholder returns.
Signal Event Report - FIGI BBG000BBS2Y0
A U.S. jury ruled against Amgen in a patent infringement lawsuit filed by Harbour BioMed, concerning antibody therapeutics. This verdict represents a significant legal setback for Amgen and its subsidiary Teneobio.
This patent loss could negatively impact Amgen's long-term competitive advantage and future revenue streams from the affected antibody therapeutics, potentially requiring licensing agreements or product adjustments. Investors should consider the financial implications of this legal defeat.